AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAR 6 - (NewsRx.com & NewsRx.net) -- Newly published data show that treatment with 5 mg Actonel (risedronate sodium tablets) daily reduced the risk of spinal fracture in postmenopausal osteoporotic patients at higher risk of fracture because of age or low bone mineral density (BMD) at the hip.
In these patients, fracture risk was reduced by 62% and 60%, respectively, at 1 year with Actonel compared with placebo. The analysis of combined data from two studies was published in the Journal of Clinical Endocrinology and Metabolism, and also shows that the fracture reduction benefits of Actonel in patients at higher risk of fracture were similar to the benefits observed in the overall populations of patients with established osteoporosis.
"The ultimate goal of osteoporosis treatment is to prevent fractures. Providing rapid fracture prevention is critical to a high-risk patient group that, if left untreated, is likely to fracture soon," said Nelson Watts, MD, director of the University of Cincinnati Bone Health Center. "In this analysis, significant reductions in fracture risk were seen at one year with Actonel and underscore the importance of early identification and treatment of patients at high risk for fracture."
To determine the effect of Actonel on new spinal fractures in patients at high risk of fracture, data were pooled from two randomized, double-blind studies (VERT-MN and VERT-NA) in 2,457 postmenopausal osteoporotic women treated with placebo or Actonel 5 mg daily. All women received 1000 mg per day calcium and up ...
Source: HighBeam Research, Actonel significantly reduces fractures in high-risk women.